5 Experimental SMA Therapies You Might Find Interesting

2.  CK-2127107 (CK-107)

news_18_Artboard 343 copy 348

In collaboration with Astellas, Cytokinetics is developing CK-2127107 (CK-107), a new skeletal muscle troponin activator as a potential treatment for people living with SMA. CK-107 has completed five Phase 1 clinical trials in healthy volunteers, and is currently the subject of two Phase 2 clinical trials.

Find out more on how CK-107 can be used to treat SMA.

Leave a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

Share This